Dichloroacetic acid
- Generic Name
- Dichloroacetic acid
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C2H2Cl2O2
- CAS Number
- 79-43-6
- Unique Ingredient Identifier
- 9LSH52S3LQ
- Background
Dichloroacetic acid, often abbreviated DCA, is an acid analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase. Early reports of its activity against brain cancer cells led patients to treat themselves with DCA, which is commercially available in non-pharmaceutical grade. A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness.
DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market.
- Associated Conditions
- -
- Associated Therapies
- -
Regulation of Brain Glucose Metabolism in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Yale University
- Target Recruit Count
- 16
- Registration Number
- NCT05317455
A Clinical Trial to Evaluate Dichloroacetate (DCA) as a Treatment for Endometriosis-associated Pain
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 30
- Registration Number
- NCT04046081
- Locations
- 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Yale University
- Target Recruit Count
- 21
- Registration Number
- NCT03356457
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance
- Conditions
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 40
- Registration Number
- NCT02469337
- Locations
- 🇬🇧
University Hospitals Nottingham Queen's Medical Centre, Nottingham, United Kingdom
Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access
- Conditions
- First Posted Date
- 2013-02-22
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- University of Florida
- Registration Number
- NCT01797276
- Locations
- 🇺🇸
University of Florida Box 100226, Gainesville, Florida, United States
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
- Conditions
- Interventions
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Daniel T. Chang
- Target Recruit Count
- 17
- Registration Number
- NCT01163487
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Imaging and Biomarkers of Hypoxia in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 28
- Registration Number
- NCT01123005
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 15
- Registration Number
- NCT01111097
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Pharmacotoxicology of Trichloroethylene Metabolites
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 2
- Registration Number
- NCT00865514
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours
- Conditions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 23
- Registration Number
- NCT00566410
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.